serodeconversion of hiv antibody-positive aids patients following treatment with v-1 immunitorserodeconversion艾滋病毒抗体阳性艾滋病患者治疗后与它们immunitor.pdfVIP

Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2009, Article ID 934579, 7 pages doi:10.1155/2009/934579 Research Article Serodeconversion of HIV Antibody-Positive AIDS Patients Following Treatment with V-1 Immunitor Orapun Metadilogkul,1 Vichai Jirathitikal,2 and Aldar S. Bourinbaiar2 1 Occupational and Environmental Medicine Association of Thailand, Rajavithi General Hospital, Ministry of Public Health, Rajavithi Road, Bangkok 10400, Thailand 2 Immunitor USA Inc., 9308 48th Avenue, College Park, MD 20740, USA Correspondence should be addressed to Aldar S. Bourinbaiar, info@ Received 30 May 2008; Revised 7 August 2008; Accepted 7 September 2008 Recommended by Ali Ouaissi It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention—serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2–58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was p